Home > Services > Cell & Gene Therapy Solution > Immune Cell Therapy Solution > LNPs Delivery System
LNPs Delivery System
Lipid nanoparticles (LNPs) are at the forefront of revolutionizing gene and cell therapy by overcoming crucial delivery challenges and significantly enhancing treatment efficacy. LNPs efficiently deliver genes and RNA molecules, enabling targeted gene therapy and personalized medicine approaches.
In the field of cell therapy, LNPs enhance immune cell functions, offering exciting opportunities for improved cancer immunotherapy, treatment of autoimmune diseases, and advancements in regenerative medicine. With their remarkable versatility and effectiveness, LNPs have become a leading non-viral delivery system, driving breakthroughs in therapeutic development and the realization of personalized treatments.
Figure 1. The workflow of mRNA–LNPs[1]
AcceGen provides a comprehensive lipid nanoparticle (LNP) RNA delivery service for mRNA-based therapeutics. LNPs efficiently deliver nucleic acids, enabling applications in gene editing, vaccines, and immune cell therapy. Our LNP technology enhances transfection efficiency, cellular uptake, and cargo release. In immune cell therapy, LNP-mediated RNA delivery supports CAR-T cell therapy, dendritic cell-based vaccines, and TCR gene therapy, improving cytotoxicity and specificity. By leveraging our services, AcceGen actively contributes to advancing precision medicine, offering personalized immunotherapies, and improving patient outcomes in various disease areas.
Application
- LNPs are a clinically advanced non-viral gene delivery system that effectively and safely deliver nucleic acids.
- LNPs overcome barriers in genetic medicine, enabling applications such as gene editing, rapid vaccine development and treatment of rare genetic and undruggable diseases.
- LNPs exhibit high nucleic acid encapsulation efficiency, potent transfection, improved tissue penetration, and low cytotoxicity and immunogenicity.
Reference
[1]. Schoenmaker, Linde. , et al. “mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.” International journal of pharmaceutics 601(2021):120586.
